Summit Therapeutics' decision to pull its $500M offering illustrates a key risk. The public knowledge that the company needs capital but was unhappy with the price creates an overhang, as investors may now wait for a future, potentially discounted, financing event, putting downward pressure on the stock.

Eli Lilly's deal chief revealed that even premium acquisition offers are frequently rebuffed by public biotech companies without negotiation. This highlights a significant valuation gap where biotech boards believe their assets are worth far more than what even well-capitalized buyers like Lilly are willing to pay, stalling potential M&A activity.

The AstraZeneca-Summit partnership is structured unconventionally. Rather than just supplying its drug for trials, AstraZeneca is making a $2B equity investment and funding R&D. This novel structure allows AZ to test multiple hypotheses while providing Summit with a crucial cash infusion.

Recent biotech deals are setting new valuation records for companies at specific early stages: preclinical (AbbVie/Capstan, ~$2B), Phase 1 (J&J/Halda, $3B), and pre-Phase 3 (Novartis/Abitivi, $12B). This signals intense demand for de-risked innovation well before late-stage data is available.

Contrary to conventional wisdom, pharmaceutical giants don't typically acquire biotechs when their valuations are at rock bottom. Like retail investors, they often wait for positive momentum and a significant stock price increase before engaging, driven by market psychology rather than pure value investing.

In a tight funding environment, a significant portion of startups now secure pharma partnerships *before* their Series A. This pre-validation has become a major draw for VCs, signaling a shift where corporate buy-in is needed to de-risk early-stage science for investors.

Astute biotech leaders leverage the tension between public financing and strategic pharma partnerships. When public markets are down, pursue pharma deals as a better source of capital. Conversely, use the threat of a public offering to negotiate more favorable terms in pharma deals, treating them as interchangeable capital sources.

With patent cliffs looming and mature assets acquired, large pharmaceutical companies are increasingly paying billion-dollar prices for early-stage and even preclinical companies. This marks a significant strategic shift in M&A towards accepting higher risk for earlier innovation.

Sanofi's $2.2 billion acquisition of Dynavax at a 39% premium highlights the high value placed on companies with approved products and a promising pipeline. This demonstrates the willingness of major pharmaceutical companies to pay significantly above market price to secure de-risked assets and expand strategic portfolios like vaccines.